Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

LENZ Therapeutics (LENZ) Financials

LENZ Therapeutics logo
$38.20 +0.83 (+2.22%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$38.49 +0.29 (+0.77%)
As of 05:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for LENZ Therapeutics

Annual Income Statements for LENZ Therapeutics

This table shows LENZ Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -68 -71 -101 -70 -50
Consolidated Net Income / (Loss)		 -68 -71 -101 -70 -50
Net Income / (Loss) Continuing Operations		 -68 -71 -101 -70 -50
Total Pre-Tax Income 		-68 -71 -101 -70 -50
Total Operating Income		 -14 -60 -106 -72 -59
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 14 60 106 72 59
Selling, General & Admin Expense		 4.38 23 33 13 29
Research & Development Expense		 9.12 38 73 60 30
Total Other Income / (Expense), net		 -55 -10 4.59 2.28 8.84
Interest & Investment Income		 - - - 2.19 8.55
Other Income / (Expense), net		 -55 -10 4.59 0.09 0.29
Income Tax Expense		 - - - -0.18 0.00
Basic Earnings per Share		 ($29.93) ($2.45) ($1.84) ($35.71) ($2.34)
Weighted Average Basic Shares Outstanding		 2.28M 28.92M 54.87M 1.96M 21.28M
Diluted Earnings per Share		 ($29.93) ($2.45) ($1.84) ($35.71) ($2.34)
Weighted Average Diluted Shares Outstanding		 2.28M 28.92M 54.87M 1.96M 21.28M
Weighted Average Basic & Diluted Shares Outstanding		 2.28M 28.92M 58.16M 58.24M 27.54M

Quarterly Income Statements for LENZ Therapeutics

This table shows LENZ Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -25 -13 -15 -19 -24 -17 -10 -10 -13 -15 -15
Consolidated Net Income / (Loss)		 -25 -13 -15 -19 -24 -17 -10 -10 -13 -15 -15
Net Income / (Loss) Continuing Operations		 -24 -13 -15 -19 -24 -17 -10 -10 -13 -15 -15
Total Pre-Tax Income 		-24 -13 -15 -19 -24 -17 -10 -10 -13 -15 -14
Total Operating Income		 -27 -13 -15 -20 -25 -16 -14 -13 -15 -17 -17
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 5.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 5.00
Operating Revenue		 - - - - - - 0.00 - - - 5.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 27 13 15 20 25 16 14 13 15 17 22
Selling, General & Admin Expense		 8.29 2.29 2.32 2.86 5.45 5.55 7.41 6.49 9.36 11 13
Research & Development Expense		 18 10 13 17 20 11 6.95 6.45 5.87 5.82 9.06
Total Other Income / (Expense), net		 2.28 -0.05 0.23 0.99 1.12 -0.56 4.10 2.73 2.57 2.31 2.45
Interest & Investment Income		 - 0.00 0.25 1.09 0.85 0.79 2.46 2.74 2.57 2.32 2.25
Other Income / (Expense), net		 2.28 -0.05 -0.02 -0.10 0.27 -1.35 1.64 -0.01 0.01 -0.01 0.20
Income Tax Expense		 - - - - - - 0.00 - - - 0.50
Basic Earnings per Share		 ($0.43) ($6.50) ($7.53) ($9.62) ($12.06) ($3.53) ($0.40) ($0.38) $1.97 ($0.53) ($0.53)
Weighted Average Basic Shares Outstanding		 54.87M 1.95M 1.96M 1.96M 1.96M 4.72M 25.61M 27.17M 21.28M 27.53M 28.08M
Diluted Earnings per Share		 ($0.43) ($6.50) ($7.53) ($9.62) ($12.06) ($3.53) ($0.40) ($0.38) $1.97 ($0.53) ($0.53)
Weighted Average Diluted Shares Outstanding		 54.87M 1.95M 1.96M 1.96M 1.96M 4.72M 25.61M 27.17M 21.28M 27.53M 28.08M
Weighted Average Basic & Diluted Shares Outstanding		 58.16M 58.10M 57.98M 58.00M 58.24M 25.53M 27.50M 27.50M 27.54M 28.15M 28.52M

Annual Cash Flow Statements for LENZ Therapeutics

This table details how cash moves in and out of LENZ Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 20 359 -329 -9.30 -15
Net Cash From Operating Activities		 -8.72 -53 -88 -60 -59
Net Cash From Continuing Operating Activities		 -8.72 -53 -88 -60 -59
Net Income / (Loss) Continuing Operations		 -68 -71 -101 -70 -50
Consolidated Net Income / (Loss)		 -68 -71 -101 -70 -50
Depreciation Expense		 0.12 0.73 2.35 0.02 0.06
Amortization Expense		 - 0.00 -1.60 -1.06 -4.02
Non-Cash Adjustments To Reconcile Net Income		 60 19 20 1.41 7.43
Changes in Operating Assets and Liabilities, net		 -0.06 -1.37 -7.30 9.41 -13
Net Cash From Investing Activities		 -1.55 -5.74 -242 -30 -154
Net Cash From Continuing Investing Activities		 -1.55 -5.74 -242 -30 -154
Purchase of Property, Plant & Equipment		 -1.55 -5.74 -6.59 -0.03 -0.47
Purchase of Investments		 - 0.00 -406 -52 -242
Sale and/or Maturity of Investments		 - 0.00 170 23 88
Net Cash From Financing Activities		 30 417 0.60 81 199
Net Cash From Continuing Financing Activities		 30 417 0.60 81 199
Repurchase of Common Equity		 - - -0.08 -2.48 0.00
Issuance of Preferred Equity		 25 166 - 83 0.00
Issuance of Common Equity		 0.26 252 0.66 0.00 80
Other Financing Activities, net		 0.00 0.03 0.02 0.20 119

Quarterly Cash Flow Statements for LENZ Therapeutics

This table details how cash moves in and out of LENZ Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Change in Cash & Equivalents		 -8.66 70 -40 -32 -7.71 165 -116 -43 -21 2.88 15
Net Cash From Operating Activities		 -22 -13 -14 -13 -21 -24 -16 -11 -9.08 -16 -12
Net Cash From Continuing Operating Activities		 -22 -13 -14 -13 -21 -24 -16 -11 -9.08 -16 -12
Net Income / (Loss) Continuing Operations		 -25 -13 -15 -19 -24 -17 -10 -10 -13 -15 -15
Consolidated Net Income / (Loss)		 -25 -13 -15 -19 -24 -17 -10 -10 -13 -15 -15
Depreciation Expense		 0.68 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.03 0.04 0.02
Amortization Expense		 -1.12 0.00 -0.02 -0.53 -0.51 -0.28 -0.96 -1.36 -1.42 -1.13 -0.89
Non-Cash Adjustments To Reconcile Net Income		 5.53 0.16 0.21 0.60 0.44 1.99 1.60 2.19 1.65 2.56 2.85
Changes in Operating Assets and Liabilities, net		 -2.92 -0.29 1.00 5.72 2.98 -9.01 -6.20 -1.21 3.33 -2.97 1.43
Net Cash From Investing Activities		 14 -0.01 -27 -18 15 18 -98 -62 -12 19 -0.41
Net Cash From Continuing Investing Activities		 14 -0.01 -27 -18 15 18 -98 -62 -12 19 -0.41
Purchase of Property, Plant & Equipment		 -1.02 -0.01 -0.02 - - 0.00 -0.13 -0.19 -0.15 -0.11 -0.24
Purchase of Investments		 -66 - - -19 -5.83 0.00 - -84 -47 -33 -58
Sale and/or Maturity of Investments		 80 0.00 - 1.50 21 18 13 22 35 52 58
Net Cash From Financing Activities		 0.24 83 - -0.57 -1.91 171 -2.14 30 0.05 0.04 26
Net Cash From Continuing Financing Activities		 0.24 83 - -0.57 -1.91 171 -2.14 30 0.05 0.04 26
Issuance of Common Equity		 0.24 0.00 - - - 53 -3.56 30 -0.09 0.00 26
Other Financing Activities, net		 0.00 0.20 - - - 118 1.43 0.04 0.14 0.04 0.20

Annual Balance Sheets for LENZ Therapeutics

This table presents LENZ Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 23 402 322 70 215
Total Current Assets		 21 382 275 67 212
Cash & Equivalents		 20 377 48 35 20
Restricted Cash		 0.04 - 0.00 0.00 0.11
Short-Term Investments		 - 0.00 220 31 189
Prepaid Expenses		 1.29 4.76 7.14 1.45 2.77
Plant, Property, & Equipment, net		 1.46 6.51 23 0.05 0.65
Total Noncurrent Assets		 0.00 14 24 3.08 2.74
Other Noncurrent Operating Assets		 0.00 14 8.59 3.08 2.74
Total Liabilities & Shareholders' Equity		 23 402 322 70 215
Total Liabilities		 32 18 26 20 11
Total Current Liabilities		 32 12 13 19 10
Accounts Payable		 0.63 2.45 2.61 5.71 4.26
Accrued Expenses		 1.89 1.52 2.59 13 6.15
Total Noncurrent Liabilities		 0.32 5.79 13 1.18 0.81
Other Noncurrent Operating Liabilities		 0.32 5.79 13 1.18 0.81
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -65 384 296 -93 204
Total Preferred & Common Equity		 -65 384 296 -93 204
Total Common Equity		 -65 384 296 -93 204
Common Stock		 5.18 525 540 2.53 349
Retained Earnings		 -71 -141 -242 -95 -145
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -1.05 0.01 0.20

Quarterly Balance Sheets for LENZ Therapeutics

This table presents LENZ Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025
Total Assets		 354 335 310 287 266 217 203 224 201 217
Total Current Assets		 327 298 270 251 239 217 199 221 198 214
Cash & Equivalents		 75 56 70 129 183 200 84 41 23 38
Restricted Cash		 - - - - - 0.11 0.11 0.11 0.11 0.11
Short-Term Investments		 247 235 194 118 51 13 112 176 171 172
Prepaid Expenses		 4.35 6.81 6.21 2.88 4.78 3.28 3.12 3.48 3.77 3.97
Plant, Property, & Equipment, net		 10 13 33 18 13 0.05 0.16 0.37 0.93 1.17
Total Noncurrent Assets		 17 23 6.62 18 15 0.60 3.13 2.93 2.47 2.56
Other Noncurrent Operating Assets		 11 9.68 6.62 18 15 0.60 3.13 2.93 2.47 2.56
Total Liabilities & Shareholders' Equity		 354 335 310 287 266 217 203 224 201 217
Total Liabilities		 15 18 34 63 62 19 9.72 8.73 9.24 11
Total Current Liabilities		 12 14 14 12 13 19 8.58 7.71 8.57 10
Accounts Payable		 3.62 3.97 1.99 2.72 3.75 7.13 4.41 2.76 3.66 2.85
Accrued Expenses		 1.34 1.65 7.91 4.37 3.45 12 4.18 4.95 4.91 7.54
Total Noncurrent Liabilities		 3.26 4.87 19 51 50 0.27 1.14 1.02 0.67 0.57
Other Noncurrent Operating Liabilities		 3.26 4.87 19 51 50 0.27 1.14 1.02 0.67 0.57
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 338 316 276 224 204 198 193 215 192 206
Total Preferred & Common Equity		 338 316 276 224 204 198 193 215 192 206
Total Common Equity		 338 316 276 224 204 198 193 215 192 206
Common Stock		 533 536 543 546 548 310 315 347 352 381
Retained Earnings		 -193 -218 -266 -322 -344 -112 -122 -132 -160 -175
Accumulated Other Comprehensive Income / (Loss)		 -1.03 -1.60 -0.47 -0.27 -0.10 -0.00 -0.06 0.52 0.12 0.04

Annual Metrics And Ratios for LENZ Therapeutics

This table displays calculated financial ratios and metrics derived from LENZ Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -2.66% -43.23% 26.84% 15.12%
EBIT Growth		 0.00% -3.55% -42.81% 28.42% 19.37%
NOPAT Growth		 0.00% -347.73% -74.77% 31.44% 19.08%
Net Income Growth		 0.00% -3.49% -42.81% 30.76% 28.87%
EPS Growth		 0.00% 91.81% 24.90% -1,840.76% 93.45%
Operating Cash Flow Growth		 0.00% -506.03% -66.46% 31.37% 1.64%
Free Cash Flow Firm Growth		 0.00% 0.00% -0.77% 71.31% -123.61%
Invested Capital Growth		 0.00% 123.88% 80.10% -218.65% 66.53%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -6.72% -0.43% 47.32%
EBIT Q/Q Growth		 0.00% 0.00% -5.81% -0.34% 51.46%
NOPAT Q/Q Growth		 0.00% 0.00% -7.98% 2.38% 55.31%
Net Income Q/Q Growth		 0.00% 0.00% -33.54% 1.28% 56.51%
EPS Q/Q Growth		 0.00% 0.00% -132.74% -48.30% -113.64%
Operating Cash Flow Q/Q Growth		 0.00% -24.27% -8.42% 2.36% 41.14%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -115.89% 57.37%
Invested Capital Q/Q Growth		 0.00% 0.00% 12.10% 49.59% -160.69%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 99.74% 100.00%
Interest Burden Percent		 100.06% 100.00% 100.00% 96.97% 85.33%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 697.68% -37.81% -29.71% -40.33% -39.07%
Cash Return on Invested Capital (CROIC)		 0.00% -1,116.78% -803.61% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 4,656.54% -32.20% -29.71% -23.66% -17.08%
Return on Equity Simple (ROE_SIMPLE)		 104.53% -18.42% -34.11% 75.47% -24.39%
Net Operating Profit after Tax (NOPAT)		 -9.45 -42 -74 -51 -41
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -297.34% -14.34% -8.21% -11.03% -6.36%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 54.69% -20.10%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -68 -71 -101 -72 -58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -68 -70 -100 -73 -62
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 1.88 0.65 0.00 3.89
Price to Tangible Book Value (P/TBV)		 0.00 1.88 0.65 0.00 3.89
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 48.76 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 2.02 -1.06 -0.97 -1.01 -1.08
Leverage Ratio		 -2.30 1.13 1.06 1.13 1.12
Compound Leverage Factor		 -2.30 1.13 1.06 1.10 0.96
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -567.43% 0.00% 0.00% 282.94% 0.00%
Common Equity to Total Capital		 667.43% 100.00% 100.00% -182.94% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -11.32 24.18 3.41 0.17 41.74
Noncontrolling Interest Sharing Ratio		 -567.43% 14.86% 0.00% 41.33% 56.28%
Liquidity Ratios		 - - - - -
Current Ratio		 0.66 31.44 21.11 3.63 20.36
Quick Ratio		 0.62 31.04 20.57 3.55 20.09
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -79 -80 -23 -51
Operating Cash Flow to CapEx		 -564.47% -920.77% -1,334.24% -201,266.67% -12,690.38%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -218.03 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -256.65 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -30 7.07 13 -15 -5.06
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 37 5.67 -28 10
Enterprise Value (EV)		 232 345 -90 230 585
Market Capitalization		 196 722 193 152 794
Book Value per Share		 ($28.64) $6.61 $5.10 ($1.60) $7.42
Tangible Book Value per Share		 ($28.64) $6.61 $5.10 ($1.60) $7.42
Total Capital		 -9.80 384 296 51 204
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -20 -377 -284 -66 -209
Capital Expenditures (CapEx)		 1.55 5.74 6.59 0.03 0.47
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -31 -7.38 -5.91 -17 -7.63
Debt-free Net Working Capital (DFNWC)		 -11 370 262 49 202
Net Working Capital (NWC)		 -11 370 262 49 202
Net Nonoperating Expense (NNE)		 59 28 27 19 8.74
Net Nonoperating Obligations (NNO)		 -20 -377 -284 -66 -209
Total Depreciation and Amortization (D&A)		 0.12 0.73 0.75 -1.04 -3.96
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.45) ($1.84) ($2.19) ($2.34)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 58.01M 54.87M 57.02M 21.28M
Adjusted Diluted Earnings per Share		 $0.00 ($2.45) ($1.84) ($2.19) ($2.34)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 58.01M 54.87M 57.02M 21.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.45) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 28.92M 58.16M 58.24M 27.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.45 -42 -74 -51 -41
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -1,708.33 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -236.25 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -1,746.95 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -274.88 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.08% -3.54% 0.00%

Quarterly Metrics And Ratios for LENZ Therapeutics

This table displays calculated financial ratios and metrics derived from LENZ Therapeutics' official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -33.95% 50.27% 40.79% 16.68% -1.26% -39.78% 8.90% 30.21% 34.14% -1.89% -28.33%
EBIT Growth		 -29.30% 51.19% 42.25% 19.11% -1.01% -37.62% 15.09% 35.13% 38.45% 2.83% -30.99%
NOPAT Growth		 -41.24% 51.40% 44.13% 24.05% 6.59% -27.52% 4.06% 34.84% 39.07% -5.24% -17.45%
Net Income Growth		 -3,257.77% 50.96% 43.22% 23.51% 3.69% -31.40% 30.37% 45.90% 46.60% 12.19% -45.43%
EPS Growth		 -106.12% -1,254.17% -1,468.75% -2,037.78% -2,704.65% 45.69% 94.69% 96.05% 116.34% 84.99% -32.50%
Operating Cash Flow Growth		 -43.84% 39.75% 38.79% 41.09% 6.51% -87.04% -16.79% 19.16% 56.71% 32.95% 27.14%
Free Cash Flow Firm Growth		 0.00% 56.98% 174.89% 212.05% 142.49% 236.73% -229.50% -235.20% -299.87% -255.34% 61.68%
Invested Capital Growth		 80.10% 31.97% -337.29% -363.85% -218.65% -225.54% 86.31% 93.53% 66.53% 86.34% 1.12%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -1.31% 49.16% -18.35% -36.67% -23.14% 74.49% 22.86% -4.70% -16.20% -8.57% 2.84%
EBIT Q/Q Growth		 0.83% 48.24% -18.21% -33.31% -23.83% 76.60% 27.06% -1.84% -17.50% -11.34% 1.68%
NOPAT Q/Q Growth		 -2.28% 52.84% -18.57% -32.80% -25.79% 80.52% 10.79% 9.80% -17.61% -11.21% 0.44%
Net Income Q/Q Growth		 0.34% 48.49% -16.23% -28.21% -25.49% 77.47% 38.41% 0.38% -23.86% -15.55% -2.00%
EPS Q/Q Growth		 4.44% -1,411.63% -15.85% -27.76% -25.36% -128.86% 88.67% 5.00% 618.42% -126.90% 0.00%
Operating Cash Flow Q/Q Growth		 -0.95% 42.94% -5.67% 3.22% -60.22% 47.82% 34.01% 33.01% 14.20% -76.79% 28.29%
Free Cash Flow Firm Q/Q Growth		 0.42% 51.75% 302.66% 15.07% -62.24% 153.72% -291.94% -20.13% 44.18% -20.68% 52.65%
Invested Capital Q/Q Growth		 12.10% -4.80% -299.10% -24.19% 49.59% -0.73% 78.29% 41.27% -160.69% 58.89% -57.12%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -350.54%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -337.14%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -333.16%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -298.24%
Tax Burden Percent		 100.50% 100.00% 100.00% 100.00% 99.25% 100.00% 100.00% 100.00% 100.01% 100.00% 103.47%
Interest Burden Percent		 100.00% 100.00% 98.32% 94.56% 96.55% 95.48% 80.63% 78.87% 83.14% 86.29% 86.52%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -29.71% -27.57% -27.26% -27.23% -40.33% -53.79% -59.04% -54.59% -39.07% -24.47% -26.25%
Cash Return on Invested Capital (CROIC)		 -803.61% -633.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7.93%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7.10%
Return on Common Equity (ROCE)		 -29.71% -27.57% -27.26% -27.23% -23.66% -53.79% -59.04% -54.59% -17.08% -24.47% -26.25%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -31.82% -34.21% -34.74% 0.00% -64.38% -63.81% -53.16% 0.00% -24.86% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -8.83 -10 -14 -17 -11 -10 -9.06 -11 -12 -12
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -236.00%
Net Nonoperating Expense Percent (NNEP)		 -1.78% -1.25% -1.48% -1.85% -3.55% -2.26% -0.09% -0.51% -1.45% -1.36% -1.53%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - 18.87% - - - -5.22% -6.17% -5.72%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 255.92%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 181.22%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 437.14%
Earnings before Interest and Taxes (EBIT)		 -24 -13 -15 -20 -25 -17 -13 -13 -15 -17 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -13 -15 -20 -25 -18 -14 -14 -17 -18 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.65 0.52 0.67 0.70 0.00 6.54 2.29 3.03 3.89 3.69 4.00
Price to Tangible Book Value (P/TBV)		 0.65 0.52 0.67 0.70 0.00 6.54 2.29 3.03 3.89 3.69 4.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 164.99
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 123.07
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.97 -0.97 -1.02 -1.04 -1.01 -1.01 -1.07 -1.08 -1.08 -1.04 -1.02
Leverage Ratio		 1.06 1.08 1.14 1.15 1.13 1.11 1.17 1.17 1.12 1.07 1.05
Compound Leverage Factor		 1.06 1.08 1.12 1.09 1.09 1.06 0.95 0.92 0.93 0.93 0.91
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 282.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% -182.94% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 4.20 2.18 0.70 0.35 2.41 40.67 27.34 45.00 42.40 45.71 44.90
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 41.33% 0.00% 0.00% 0.00% 56.28% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 21.11 18.85 20.47 19.05 3.63 11.47 23.23 28.63 20.36 23.09 20.54
Quick Ratio		 20.57 18.42 20.10 18.66 3.55 11.29 22.85 28.16 20.09 22.64 20.15
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -24 -12 24 27 10 16 -31 -37 -21 -25 -12
Operating Cash Flow to CapEx		 -2,196.77% -213,300.00% -56,350.00% 0.00% 0.00% 0.00% -11,875.94% -5,688.71% -6,092.62% -14,590.00% -4,795.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.50
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 13 12 -24 -30 -15 -15 -3.31 -1.94 -5.06 -2.08 -3.27
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.52
Increase / (Decrease) in Invested Capital		 5.67 2.94 -34 -41 -28 -27 21 28 10 13 0.04
Enterprise Value (EV)		 -90 -122 -96 -90 230 1,082 245 436 585 514 615
Market Capitalization		 193 143 151 144 152 1,295 441 653 794 708 825
Book Value per Share		 $5.10 $4.75 $3.86 $3.52 ($1.60) $42.01 $7.56 $7.83 $7.42 $6.97 $7.33
Tangible Book Value per Share		 $5.10 $4.75 $3.86 $3.52 ($1.60) $42.01 $7.56 $7.83 $7.42 $6.97 $7.33
Total Capital		 296 276 224 204 51 198 193 215 204 192 206
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -284 -264 -247 -234 -66 -213 -196 -217 -209 -194 -210
Capital Expenditures (CapEx)		 1.02 0.01 0.02 0.00 0.00 0.00 0.13 0.19 0.15 0.11 0.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.91 -8.13 -7.76 -7.74 -17 -16 -5.46 -4.23 -7.63 -4.80 -6.43
Debt-free Net Working Capital (DFNWC)		 262 256 239 226 49 198 191 213 202 189 203
Net Working Capital (NWC)		 262 256 239 226 49 198 191 213 202 189 203
Net Nonoperating Expense (NNE)		 5.87 3.84 4.25 4.97 6.20 5.39 0.21 1.15 1.99 2.77 3.11
Net Nonoperating Obligations (NNO)		 -284 -264 -248 -234 -66 -213 -196 -217 -209 -194 -210
Total Depreciation and Amortization (D&A)		 -0.44 0.00 -0.02 -0.52 -0.51 -0.27 -0.94 -1.35 -1.40 -1.10 -0.87
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -128.58%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,064.08%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,064.08%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.43) ($0.43) ($0.97) ($0.39) ($12.06) ($3.53) ($0.40) ($0.38) $1.97 ($0.53) ($0.53)
Adjusted Weighted Average Basic Shares Outstanding		 54.87M 55.86M 56.75M 57.26M 1.96M 4.72M 25.61M 27.17M 21.28M 27.53M 28.08M
Adjusted Diluted Earnings per Share		 ($0.43) ($0.43) ($0.97) ($0.39) ($12.06) ($3.53) ($0.40) ($0.38) $1.97 ($0.53) ($0.53)
Adjusted Weighted Average Diluted Shares Outstanding		 54.87M 55.86M 56.75M 57.26M 1.96M 4.72M 25.61M 27.17M 21.28M 27.53M 28.08M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 58.16M 58.10M 57.98M 58.00M 58.24M 25.53M 27.50M 27.50M 27.54M 28.15M 28.52M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -8.83 -10 -14 -17 -11 -10 -9.06 -11 -12 -12
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -236.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -288.24%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.08% 0.00% 0.00% 0.00% -3.54% 0.00% 0.00% 0.44% 0.00% 0.00% 0.00%

Key Financial Trends

LENZ Therapeutics Financial Analysis (Last 4 Years through Q2 2025)

Analyzing LENZ Therapeutics’ quarterly financial statements from Q2 2022 to Q2 2025 reveals several notable trends in revenue, expenses, net income, cash flows, and the balance sheet structure.

  • LENZ reported $5 million in total revenue in Q2 2025, marking the first quarter with positive revenue after several quarters of zero reported revenue, indicating potential progress in commercialization or milestone achievements.
  • Cash & Equivalents grew significantly from $69.8 million in Q1 2023 to $37.6 million in Q2 2025, despite fluctuations, reflecting ongoing capital raises and investment management.
  • Common equity increased from $276 million in Q1 2023 to $206 million in Q2 2025, showing sustained capital investment despite accumulated losses.
  • LENZ successfully raised funds via common equity issuance, most notably $26.3 million in Q2 2025 and large financings in prior periods (e.g., $83.2 million in Q1 2023), helping preserve liquidity.
  • Operating expenses remain consistently high, with R&D and SG&A totaling approximately $21.9 million in Q2 2025, slightly up from prior quarters, reflecting robust pipeline investment.
  • Investments management is active, with considerable purchases and sales of short-term investments (e.g., ~$58 million purchase and sale in Q2 2025), suggesting a focus on liquidity and capital preservation.
  • Total assets decreased from ~$310 million in Q1 2023 to ~$217 million by Q2 2025, mainly due to declining investment balances and cash utilization for operations.
  • Weighted average shares outstanding have increased substantially from roughly 2 million in early 2023 to ~28 million shares in 2025, indicating dilution due to capital raises.
  • LENZ reported no revenue in most quarters prior to Q2 2025, resulting in consistent net losses—e.g., a net loss of $14.9 million in Q2 2025, $14.6 million in Q1 2025, and losses exceeding $20 million in multiple quarters in 2023.
  • Net operating cash flow is negative in all recent quarters, reaching -$11.5 million in Q2 2025 and -$16.1 million in Q1 2025, highlighting cash burn from ongoing operations.
  • Retained earnings show deep accumulated losses: -$174.5 million in Q2 2025 and -$266 million as of Q1 2023, reflecting cumulative negative net income impacting shareholder equity.
  • Earnings per share remain negative with a diluted EPS of -$0.53 reported in Q2 2025, reflecting unprofitable operations despite revenue recognition.
  • Total liabilities slightly increased over time but stayed reasonable compared to equity, with notable accrued expenses and payables that need management attention.

Summary: LENZ Therapeutics is an early-stage biopharmaceutical company showing initial revenue in Q2 2025 amidst a multi-year trend of net losses and negative cash flow from operations. The company is heavily investing in R&D and SG&A, resulting in ongoing losses and accumulated deficits. Significant capital raises have provided liquidity, but shareholder dilution has increased. Investment in short-term securities helps manage cash reserves. Retail investors should be aware that the company remains unprofitable, with high cash burn and dependency on financing, typical for a clinical-stage biotech firm advancing its pipeline.

08/29/25 05:58 AM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About LENZ Therapeutics' Financials

When does LENZ Therapeutics' fiscal year end?

According to the most recent income statement we have on file, LENZ Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has LENZ Therapeutics' net income changed over the last 4 years?

LENZ Therapeutics' net income appears to be on a downward trend, with a most recent value of -$49.77 million in 2024, falling from -$68.37 million in 2020. The previous period was -$69.97 million in 2023. Find out what analysts predict for LENZ Therapeutics in the coming months.

What is LENZ Therapeutics' operating income?
LENZ Therapeutics' total operating income in 2024 was -$58.61 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $58.61 million
How has LENZ Therapeutics' revenue changed over the last 4 years?

Over the last 4 years, LENZ Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does LENZ Therapeutics have?

LENZ Therapeutics' total liabilities were at $11.22 million at the end of 2024, a 43.0% decrease from 2023, and a 65.3% decrease since 2020.

How much cash does LENZ Therapeutics have?

In the past 4 years, LENZ Therapeutics' cash and equivalents has ranged from $19.78 million in 2020 to $376.98 million in 2021, and is currently $20.16 million as of their latest financial filing in 2024.

How has LENZ Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, LENZ Therapeutics' book value per share changed from -28.64 in 2020 to 7.42 in 2024, a change of -125.9%.


Related Companies

This page (NASDAQ:LENZ) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...
Brownstone Research | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel